OncoSec Medical (ONCS) Hits New 12-Month Low on Analyst Downgrade
OncoSec Medical Inc (NASDAQ:ONCS)’s share price hit a new 52-week low on Tuesday after HC Wainwright downgraded the stock from a buy rating to a neutral rating. The company traded as low as $0.68 and last traded at $0.84, with a volume of 361585 shares traded. The stock had previously closed at $1.74.
A number of other equities analysts have also weighed in on the stock. Piper Jaffray Companies cut their target price on shares of OncoSec Medical from $5.00 to $3.00 and set an “overweight” rating for the company in a research report on Tuesday. Dawson James reiterated a “buy” rating on shares of OncoSec Medical in a research report on Monday, July 16th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $4.00.
A number of large investors have recently modified their holdings of ONCS. Millennium Management LLC boosted its position in OncoSec Medical by 2,073.8% during the first quarter. Millennium Management LLC now owns 1,000,576 shares of the biotechnology company’s stock worth $1,881,000 after purchasing an additional 954,547 shares during the period. Nexthera Capital LP boosted its position in OncoSec Medical by 26.6% during the second quarter. Nexthera Capital LP now owns 2,614,297 shares of the biotechnology company’s stock worth $3,608,000 after purchasing an additional 550,000 shares during the period. 683 Capital Management LLC bought a new position in OncoSec Medical during the second quarter worth about $414,000. BlackRock Inc. boosted its position in OncoSec Medical by 1,303.5% during the second quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after purchasing an additional 221,916 shares during the period. Finally, DRW Securities LLC boosted its position in OncoSec Medical by 157.1% during the second quarter. DRW Securities LLC now owns 180,000 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 110,000 shares during the period. Hedge funds and other institutional investors own 23.13% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/11/07/oncosec-medical-oncs-hits-new-12-month-low-on-analyst-downgrade.html.
About OncoSec Medical (NASDAQ:ONCS)
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.